clinically relevant drug transporters
Protein Profiles: Drug Transporters
June 28 by Pharma IQDrug transporters are vitally important to understanding pharmacokinetics of a drug and for assessing the possibility of drug-drug interactions. Many were originally of interest at their bacterial h...
Trends in Computational Toxicology & Critical Success Factors for Transporter Studies- Full Interview with Tobias Noeske
June 27 by Pharmaceuticals & Biotechnology Editor
In this exclusive interview Tobias Noeske, Associate Principal Scientist from AstraZeneca, speaks to Andrea Charles from Pharma IQ, about the recent trends in computational toxicology and...
How High Level Information and Hypothesis-Driven Research can Accelerate Industrial Drug Design- Full Interview with Dr Simon Newstead
June 27 by Pharmaceuticals & Biotechnology Editor
Dr Simon Newstead is a lecturer in membrane protein crystallography at the University of Oxford. In this interview, he explores why uptake transporters are important in drug development and he explo...
Trends in Computational Toxicology & Critical Success Factors for Transporter Studies
May 30 by Andrea CharlesIn this exclusive interview Tobias Noeske, Associate Principal Scientist from AstraZeneca, speaks to Andrea Charles from Pharma IQ. Noeske describes how AstraZeneca are reducing compound...
Pharma Industry Report: A Global Guide to Clinically Relevant Drug Transporters
May 24 by Pharmaceuticals & Biotechnology Editor
In this 10 page pharma industry report we look at drug transporter outsourcing, intelligent drug development applied to clinically relevant drug transporters and drug transporters in ADME....
Intelligent Drug Development Applied to Drug Transporters
May 17 by Gerald ClarkeDrug development is growing up. Sophisticated, standardised, smart methods of developing new chemical entities (NCEs) are now the order of the day. No topic shows this better than drug transporter p...
Addex Therapeutics: Implications of Transporter Regulatory Themes in Drug Development
February 26 by Niamh MadiganSonia Poli, VP for Non Clinical Development at Addex Therapeutics, a small biotech built in Geneva explains how the new FDA and EMA guidelines will impact their business. She looks at the daily chal...
Global Guide to Drug Transporters
October 15 by Pharmaceuticals & Biotechnology Editor
Pharma IQ in conjunction with the 3rd Annual Clinically Relevant Drug Transporters prepared this Global Guide to Drug Transporters, the definitive resource for professionals in the drug transportati...
FDA Draft Guidance 2012: Drug Interaction Studies- Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations
May 29 by Pharmaceuticals & Biotechnology Editor
This guidance provides recommendations for sponsors of new drug applications (NDAs) and biologics license applications (BLAs) for therapeutic biologics regulated by CDER regarding in vitro and in vi...
Genome-Wide Assessment of the Carriers Involved In The Cellular Uptake of Drugs: A Model System in Yeast
May 29 by Pharmaceuticals & Biotechnology Editor
Abstract Background: The uptake of drugs into cells has traditionally been considered to be predominantly via passive diffusion through the bilayer portion of the cell membrane. The recent recogn...
Clinically Relevant Drug Transporters: Understanding DDI with a View to Better Prediction and Control
December 15 by Andrea CharlesHow is the industry seeking to understanding DDI with a view to better prediction and control? How has the current technology landscape changed following the publication of the ITC white paper?...
Clinically Relevant Drug Transporters: What Progress is to be Expected in 2012?
December 08 by Pharma IQResearch into drug transporters forms an increasingly important part of the non-clinical development phase, with new fields such as pharmacogenomics offering new approaches to an area that is increa...
